Ventyx Biosciences Inc. (NASDAQ:VTYX)
Old Forum Content for VTYX
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- woodman: $VTYX continues to gap-fill.
- MongosPawn: @woodman $VTYX Half of my stops hit. A triple is still good, right? Thanks again @woodman.
- woodman: @MongosPawn $VTYX - It beats a sharp stick in the eye. Congrats.
- ssoha20: @woodman $VTYX what happening with $EFTR it the swings are quite high in % terms
- woodman: @ssoha20 $VTYX $EFTR - I glean nothing very out of the ordinary for a tiny market cap stock. Volume has picked up over the last couple weeks. Perhaps in anticipation of the data update expected this month.
- ssoha20: @woodman $VTYX $EFTR I booked some gains earlier now holding till we get the news
- woodman: @ssoha20 $VTYX $EFTR - Fingers crossed. Zero guarantees.
- DavidK: $VTYX- up big . @WOODMAN , you follow this .? I can’t recall
- woodman: @DavidK $VTYX - I'm aware of it as a company that is working on a different Mechanism of Action (MOA) for obesity. I don't own it.
- DavidK: @woodman $VTYX 👍
- woodman: $ZVSA - I bought this Friday right at close at $0.82, and added at open today at $1.47. It's at $2.24 now and halted. This is going a little crazy because of a new mechanism of action (MOA) for obesity. The CEO will be presenting at the BIO Healthcar ...
- shoredriver: $VTYX....rolling bio dumpster fire du jour...down75%t
- sgiseller: @shoredriver $VTYX despite the reality, firms still pumping this trash Reiterates Stifel: Buy to Buy 10/10/2023 Reiterates HC Wainwright & Co.: Buy to Buy 10/10/2023 Maintains Morgan Stanley: Overweight to Overweight 8/29/2023 Aint that sweet
| Stock Price | $7.08 |
| Change | 83.55% |
| Volume | 109,351,000 |
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Request Video of VTYXAlready a member? Sign in here.
Past Month
Leading Peers
-
$8.95 415.78%
-
$179.78 130.11%
-
$11.00 104.72%
Past Month
Lagging Peers
-
$9.41 -174.92%
-
$11.80 -55.18%
-
$5.58 -49.42%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!